Recce Pharmaceuticals — Phase III Indonesian DFI trial underway
Recce has reached a key milestone with the start of patient dosing in its Phase III Indonesian-focused study of the topical gel formulation (R327G)...
213 Views
Recce Pharmaceuticals — Funding secured to start Phase III pivotal trials
Recce is raising up to A$15.8m in equity fundraising through a now-completed A$5.0m share placement and an entitlement offer for remaining...
262 Views
Recce Pharmaceuticals — Gearing up for an eventful year for R327G
Recce is preparing to start a registrational Indonesian Phase III study of the topical gel formulation (R327G) of its lead anti-infective...
551 Views
Recce Pharmaceuticals — Positive R327G Phase II ABSSSI study results
Recce has reported positive results from its open-label Phase II study assessing RECCE® 327 topical gel (R327G) in patients with acute bacterial...
156 Views
APAC Healthcare Weekly (May 18)-Hengrui Medicine, Wuxi Biologics, Chugai, GC Biopharma, Mayne Pharma
Jiangsu Hengrui launches HK IPO. Wuxi Biologics to sell Germany plant. Chugai got Japan approval for gene therapy. Mayne Pharma was hit as FDA...
596 Views